Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Genetics

Background:

• Apolipoprotein A-I(Milano) (apoA-I(M)) is a naturally occurring variant of apoA-I.
• ApoA-I(M) carriers exhibit reduced atherosclerosis despite low HDL cholesterol, suggesting a protective role.
• The apoA-I(M) variant has a cysteine for arginine substitution at position 173.

Purpose of the Study:

• To evaluate the therapeutic potential of synthetic HDL (sHDL) composed of dimeric apoA-I(M) and phospholipids.
• To assess the efficacy of apoA-I(M)/A-I(M) sHDL in cardiovascular disease treatment.

Main Methods:

• Development of sHDL using recombinant dimeric apoA-I(M) and phospholipids.
• Administration of sHDL via single or multiple injections in preclinical models.
• Clinical evaluation in a phase II trial involving patients with acute coronary syndromes.

Main Results:

• sHDL induced regression of atherosclerotic plaques.
• sHDL prevented arterial restenosis and limited cardiac dysfunction post-ischemia/reperfusion.
• Phase II trial demonstrated significant reduction in atheroma burden with short-term apoA-I(M)/A-I(M) sHDL treatment.

Conclusions:

• ApoA-I(M)/A-I(M) sHDL is effective in treating various cardiovascular conditions.
• This sHDL therapy shows promise for reducing atherosclerotic burden and improving cardiovascular outcomes.
• ApoA-I(M)/A-I(M) sHDL represents a potential new therapeutic strategy for cardiovascular diseases.